ClinicalTrials.gg
Active, not recruitingNCT07266558Updated Sep 28, 2026

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

A Phase 4 interventional study of mRNA-1273 and mRNA-1283 in SARS-CoV-2, sponsored by ModernaTX, Inc.. Active, not recruiting at 150 sites in United States. Open to participants aged 50 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 4, Interventional, and Prevention

Updated Sep 28, 2026Enrollment updatedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30,000
Allocation
Randomized
Ages
50 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.

Enrollment
3rd of 36
30,000 · median 499
Started
2025
with 1 other
Phase 4
7 of 36
2 open now
Registered
34th of 36
by date
Lead sponsor
11 of 36
ModernaTX, Inc.

Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 3rd largest by enrollment, is one of 2 that started in 2025, is one of 7 in phase 4, and was the 34th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About 2019-nCoV Vaccine mRNA-1273

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 50 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID-19.

03

Conditions studied

  • SARS-CoV-2

Browse trials for

Keywords

  • mRNA-1273
  • mRNA-1283
  • SARS-CoV-2
  • mRNA vaccine
  • Coronavirus
  • Messenger RNA
  • COVID-19
  • COVID-19 Vaccine
  • Moderna
04

In context

COVID-19 Reclassified

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

This study's enrollment of 30,000 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy and without underlying medical conditions that may put them at higher risk of experiencing severe outcomes of COVID-19, as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.

Key Exclusion Criteria:

  • History of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 3 months prior to enrollment.
  • Acutely ill or febrile within 72 hours prior to or at the Screening Visit or Day 1.
  • Receipt of any of the following:

    • COVID-19 vaccine within 3 months prior to enrollment,
    • Any licensed non COVID-19 vaccine within 28 days before or planned receipt within 28 days after the study intervention, except an influenza vaccine, which may be given 14 days before or after receipt of the study intervention,
    • at ≥10 milligrams (mg)/day of prednisone or equivalent for >14 days in total within 90 days prior to Day 1 or is anticipating the need for corticosteroids at any time during the study or,
    • Systemic treatment within 180 days prior to the Screening or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study.
  • Has donated ≥450 mL of blood products within 28 days prior to the Screening Visit or plans to donate blood products within 28 days post study injection.
  • Has participated in an clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to do so while participating in this study.

Note: Additional inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30,000 participants (actual)

Study arms

  • Experimental
    mRNA-1273 (Variant Formulation)

    Participants will receive a single intramuscular (IM) injection of mRNA-1273 on Day 1.

    Biological: mRNA-1273

  • Experimental
    mRNA-1283 (Variant Formulation)

    Participants will receive a single IM injection of mRNA-1283 on Day 1.

    Biological: mRNA-1283

  • Placebo comparator
    Placebo

    Participants will receive a single IM injection of placebo on Day 1.

    Biological: Placebo

Interventions

  • BiologicalmRNA-1273

    Sterile liquid for injection

  • BiologicalmRNA-1283

    Sterile liquid for injection

  • BiologicalPlacebo

    0.9% sodium chloride (normal saline) injection

07

What researchers measure

Primary outcomes

  1. VE of mRNA-1273 (Variant Formulation) to Prevent the First Event of COVID-19 after Study Injection

    The VE is defined as the percent reduction in the hazard of the first event of COVID-19 after study injection (each vaccine arm versus placebo) and will be estimated using 1-hazard ratio (HR).

    Time frame: Day 1 through Day 181

  2. Vaccine Efficacy (VE) of mRNA-1283 (Variant Formulation) to Prevent the First Event of COVID-19 after Study Injection

    The VE is defined as the percent reduction in the hazard of the first event of COVID-19 after study injection (each vaccine arm versus placebo) and will be estimated using 1-hazard ratio (HR).

    Time frame: Day 1 through Day 181

  3. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Day 1 through Day 28

  4. Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs of Special Interest (AESIs), and AEs Leading to Discontinuation

    Time frame: Day 1 through Day 181

Secondary outcomes

  1. Number of Participants with a First Event of Severe COVID-19 after Study Injection

    Time frame: Day 1 through Day 181

08

Study locations

150 sites

Showing the first 100 of 150 sites. Choose a country and city above to see the rest.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jun 2027, 18 months after the start.

Of 44 industry-sponsored phase 4 interventional studies under COVID-19, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 18 months is above that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Dec 5, 2025
StartActual
Nov 26, 2025
Primary completionEst.
Jun 16, 2027
CompletionEst.
Jun 16, 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
2 edited
What changed in the outcomes
  • EditedVE of mRNA-1273 (Variant Formulation) to Prevent the First Event of Symptomatic COVID-19 after Study InjectionTime frame: Day 1 through Day 181
  • EditedVaccine Efficacy (VE) of mRNA-1283 (Variant Formulation) to Prevent the First Event of Symptomatic COVID-19 after Study InjectionTime frame: Day 1 through Day 181
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedVE of mRNA-1273 (Variant Formulation) to Prevent the First Event of Symptomatic COVID-19 after Study InjectionTime frame: Day 1 through Day 181
    • EditedVaccine Efficacy (VE) of mRNA-1283 (Variant Formulation) to Prevent the First Event of Symptomatic COVID-19 after Study InjectionTime frame: Day 1 through Day 181
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07266558
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Nov 26, 2025
Primary completion
Jun 16, 2027 (estimated)
Completion
Jun 16, 2027 (estimated)
Last update
Sep 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 2019-nCoV Vaccine mRNA-1273 · MRNA-1283

Start the discussion